Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Liquid biopsy: measuring circulating H3K27Me3-nucleosomes in Lung Cancer patients is a strong prognostic biomarker and a potential aid in treatment selection

Thursday, May 8, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses a study on liquid biopsy that measures circulating H3K27Me3-nucleosomes in lung cancer patients. This biomarker has been identified as a strong prognostic indicator and could assist in treatment selection. The findings were presented at the ISMRC 2025, highlighting their significance in the field of oncology.
Price reaction · baseline $10.4 (2025-05-08T14:22:00.000Z) · hit during market hours · 2 other VNRX headline(s) in the window, move may be shared
day 0 close · peak
-0.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • The study identifies a strong prognostic biomarker for lung cancer.
  • It offers potential aid in treatment selection for patients.
  • The research was presented at a reputable conference (ISMRC 2025).

Full Press Release Details

Paper titled: Liquid biopsy: measuring circulating H3K27Me3-nucleosomes in Lung Cancer patients is a strong prognostic biomarker and a potential aid in treatment selection
Marie Piecyk, Emmanuel Grolleau, Gaelle Lescuyer, Sébastien Couraud, Patrick Merle, Patrick Mas, Sébastien Larive, Michael Duruisseaux, Oriane Pelton, Gwenaelle Schnoering, Aristotelis Kotronoulas, Julie Candiracci, Léa Payen, Marielle Herzog
Presented at ISMRC 2025

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What is the main focus of the study?

The study focuses on measuring circulating H3K27Me3-nucleosomes as a prognostic biomarker in lung cancer patients.

Where was the research presented?

The research was presented at the ISMRC 2025 conference.

How does this biomarker aid in treatment?

The H3K27Me3-nucleosome biomarker may assist in selecting appropriate treatments for lung cancer patients.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare liquid biopsy H3K27Me3 lung cancer biomarker treatment selection
Last updated: May 8, 2025

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk